


**CLAIMS:**

1. A chemical compound represented by general formula (I)



5

or a pharmaceutically acceptable salt thereof, wherein

$R^o$ ,  $R^m$  and  $R^p$  independently of each other represent

hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;

10 with the proviso that not all three of  $R^o$ ,  $R^m$  and  $R^p$  represent hydrogen;

$R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  independently of each other represent

hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;

15 with the proviso that the compound is not

*N*-(3-Trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea.

2. The compound of claim 1, wherein

20  $R^o$  represents hydrogen;

$R^m$  represents hydrogen; and

$R^p$  represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

3. The compound of claim 1, wherein

25  $R^o$  represents hydrogen;

$R^p$  represents hydrogen; and

$R^m$  represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

4. The compound of any one of claims 1-3, wherein

30  $R^3$ ,  $R^4$  and  $R^5$  represent hydrogen; and

$R^2$  represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

5. The compound of any one of claims 1-3, wherein  
 $R^2$ ,  $R^4$  and  $R^5$  represent hydrogen; and  
 $R^3$  represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

5 6. The compound of any one of claims 1-3, wherein  
 $R^2$ ,  $R^3$  and  $R^5$  represent hydrogen; and  
 $R^4$  represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

7. The compound of any one of claims 1-3, wherein  
10  $R^2$  and  $R^5$  represent hydrogen; and  
 $R^3$  and  $R^4$  independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

8. The compound of any one of claims 1-3, wherein  
15  $R^2$  and  $R^4$  represent hydrogen; and  
 $R^3$  and  $R^5$  independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

9. The compound of claim 1, being  
20  $N$ -(4-Chloro-3-trifluoromethyl-phenyl)- $N'$ -[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;  
 $N$ -(3-Trifluoromethyl-phenyl)- $N'$ -[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
 $N$ -(4-Chloro-3-trifluoromethyl-phenyl)- $N'$ -[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
25  $N$ -(3,5-Dichloro-phenyl)- $N'$ -[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Difluoro-phenyl)- $N'$ -[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Dichloro-phenyl)- $N'$ -[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Difluoro-phenyl)- $N'$ -[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;  
 $N$ -(3-Trifluoromethyl-phenyl)- $N'$ -[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-5-yl]-urea;  
30  $N$ -(4-Chloro-3-trifluoromethyl-phenyl)- $N'$ -[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Dichloro-phenyl)- $N'$ -[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Difluoro-phenyl)- $N'$ -[4'-fluoro-2-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;  
35  $N$ -(4-Fluoro-3-trifluoromethyl-phenyl)- $N'$ -[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Bis-trifluoromethyl-phenyl)- $N'$ -[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;  
 $N$ -(3,5-Bis-trifluoromethyl-phenyl)- $N'$ -[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

5 *N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

10 *N*-(2-Bromo-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Bromo-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Bromo-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Fluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

15 *N*-(2-Fluoro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Fluoro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Fluoro-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Chloro-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Bromo-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

20 *N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Chloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(2-Chloro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(2-Chloro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(3,5-Dichloro-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

25 *N*-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;

*N*-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;

*N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-

30 biphenyl-4-yl]-urea;

*N*-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;

35 *N*-(3,5-Difluoro-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

*N*-(3-Bromo-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(4-Chloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

*N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N*'-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;  
or a pharmaceutically acceptable salt thereof.

- 5 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1-9, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
- 10 11. The use of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to the blockade of chloride channels.
- 15 12. The use according to claim 11, wherein the disease, disorder or condition responsive to the blockade of chloride channels is a bone metabolic disease, an osteoclast related bone disease, or a disease, disorder or condition that is responsive to inhibition of angiogenesis.
- 20 13. A method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to the blockade of chloride channels, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-9, or a pharmaceutically acceptable salt thereof.
- 25